Patent: 8,663,945
✉ Email this page to a colleague
Summary for Patent: 8,663,945
Title: | Methods of producing anti-TNF-alpha antibodies in mammalian cell culture |
Abstract: | The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. |
Inventor(s): | Pla; Itzcoatl A. (Worcester, MA), Matuck; Joseph C. (Worcester, MA), Fann; John C. (Shrewsbury, MA), Schulz; Christof (Ayer, MA), Roy; Nicole A. (Worcester, MA), Bruton; David F. (Enfield, CT), McIntire; James (Castro Valley, CA), Yu-Hsiang; David Chang (Solana Beach, CA), Seewoester; Thomas (Simi Valley, CA) |
Assignee: | AbbVie Inc (North Chicago, IL) |
Application Number: | 13/308,075 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,663,945 |
Patent Claims: | see list of patent claims |
Details for Patent 8,663,945
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | December 31, 2002 | ⤷ Sign Up | 2026-09-13 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | February 21, 2008 | ⤷ Sign Up | 2026-09-13 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | April 24, 2013 | ⤷ Sign Up | 2026-09-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |